StreetInsider.com News Articles

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx’s industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

Mon, 09 Mar 2026 08:30:00 -0400

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. GeneDx will present 18 accepted abstracts, including three platform presentations and two rapid fire poster talks, with research spanning sequencing innovations, breakthroughs in AI-supported interpretation, novel gene-disease discoveries, the real-world impact of earlier

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

Mon, 09 Mar 2026 08:30:00 -0400

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

Mon, 09 Mar 2026 08:30:00 -0400

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

Mon, 09 Mar 2026 08:30:00 -0400

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

Mon, 09 Mar 2026 08:30:00 -0400

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

Mon, 09 Mar 2026 08:30:00 -0400

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

Mon, 09 Mar 2026 08:30:00 -0400

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

Mon, 09 Mar 2026 08:30:00 -0400

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

Mon, 09 Mar 2026 08:30:00 -0400

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

Mon, 09 Mar 2026 08:30:00 -0400

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

Form 4 GeneDx Holdings Corp. For: Mar 06 Filed by: Feeley Kevin

Mon, 09 Mar 2026 07:56:00 -0400

si-local-file:///var/storage/secattach/20260309/26129028.html